Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

Insmed is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints.

Liquidia Technologies ($LQDA) announced an update on their ongoing clinical study. Liquidia Technologies (LQDA) has announced plans for a Phase 3 ...

Investing.com -- Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

US FDA approves GSK’s Exdensur for the treatment of severe asthma: London, UK Thursday, December 18, 2025, 11:00 Hrs [IST] GSK plc announced that the US Food and Drug Administra ...

A Brazilian study involving nearly 900 participants under the age of 40 reinforces the idea that premature lung aging is ...

A popular material for kitchen countertops has been linked to a life-threatening lung disease, silicosis. Health officials in ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...

The TO_AITION project, completed this month (December 2025), has been investigating the biological causes of inflammation ...